molecules, brain-derived chemokines facilitate immune cell transmigration into the inflamed brain tissue. Neutrophils are recruited through the specific interaction of CXCL1 and CXCL2/3, which are strongly upregulated in ischemic brains, with the neutrophil-specific receptor CXCR2. 13 In addition to enrollment of neutrophils, CXCR2 is supposed to mediate neutrophil release from the bone marrow into the blood in response to inflammatory challenges. 14 In view of our earlier findings, 4 we were interested whether neutrophils contribute to the exacerbation of ischemic brain injury induced by hyperlipidemia. Therefore, we investigated how the antagonization of the neutrophil-specific chemokine receptor CXCR2 by means of a selective pharmacological inhibitor or a neutralizing CXCR2 antiserum influenced ischemic brain injury and functional recovery in hyperlipidemic ApoE −/− mice; furthermore, investigating consequences of CXCR2 antagonization on peripheral neutrophil homeostasis and phenotype, as well as on cerebral neutrophil infiltration.
Materials and Methods

Animals and Group Allocation
Experiments were performed in accordance to the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines and the National Institutes of Health (NIH) Guidelines for the Care and Use of Laboratory Animals with local government approval. Seven-to 8-week old wild-type (C57BL/6J, Harlan) and ApoE −/− male mice, which were generated on the same C57BL/6 background, were either fed with a normal chow or a cholesterol-rich chow (Western diet; TD.88137 Adjusted Calories Diet, Harlan Laboratories) for 6 weeks and submitted to 20 minutes of left-sided middle cerebral artery occlusion (MCAO) or sham surgery. Animals were randomly attributed to treatment paradigms, and experimenters were blinded at all stages of interventions and data analysis. The selective CXCR2 antagonist SB225002 (2 mg/kg, Merck, Darmstadt) or vehicle (1% dimethyl sulfoxide in PBS) was injected intraperitoneally at 0, 24, and 48 hours post ischemia. In other experiments, CXCR2 was specifically blocked by intraperitoneal injection of a neutralizing rabbit anti-CXCR2 serum (300 µL) at 0, 24, and 48 hours post ischemia. 15 In the latter studies, normal rabbit serum served as control. In some experiments, neutrophils were depleted by intraperitoneal injection of 200 µg antimouse Ly6G (Clone 1A8, BioXcell) 24 hours before and 24 hours after ischemia. In these experiments, 200 µg of an isotype control antibody (Clone 2A3, BioXcell) was delivered as control. 11 A total of 352 male mice (184 C57Bl/6J, 168 ApoE −/− ) were examined. These mice were randomly assigned to the following groups: wild-type normolipidemic/sham/vehicle (n=18), wild-type normolipidemic/MCAO/ vehicle (n=47), wild-type normolipidemic/sham/CXCR2 antagonist (n=18), wild-type normolipidemic/MCAO/CXCR2 antagonist (n=47), ApoE −/− hyperlipidemic/sham/vehicle (n=18), ApoE −/− hyperlipidemic/MCAO/vehicle (n=39), ApoE −/− hyperlipidemic/sham/CXCR2 antagonist (n=18), ApoE −/− hyperlipidemic/MCAO/CXCR2 antagonist (n=39), wild-type normolipidemic/MCAO/normal rabbit serum (n=9), wild-type normolipidemic/MCAO/anti-CXCR2 (n=9), ApoE −/− hyperlipidemic/MCAO/normal rabbit serum (n=9), ApoE −/− hyperlipidemic/MCAO/anti-CXCR2 (n=9), wild-type normolipidemic/ MCAO/isotype/vehicle (n=9), wild-type normolipidemic/MCAO/ isotype/CXCR2 antagonist (n=9), wild-type normolipidemic/MCAO/ anti-Ly6G/vehicle (n=9), wild-type normolipidemic/MCAO/antiLy6G/CXCR2 antagonist (n=9), ApoE −/− hyperlipidemic/MCAO/isotype/vehicle (n=9), ApoE −/− hyperlipidemic/MCAO/isotype/CXCR2 antagonist (n=9), ApoE −/− hyperlipidemic/MCAO/anti-Ly6G/vehicle (n=9), and ApoE −/− hyperlipidemic/MCAO/anti-Ly6G/CXCR2 antagonist (n=9). The groups were further divided into 4 subgroups (1) to assess functional deficits at 4, 7, and 14 days post ischemia; (2) to determine infarct volumes and for immunohistochemistry; (3) to quantify leukocyte subsets in blood, bone marrow, and brain at 3 days post ischemia; and (4) to analyze mRNA expression via real-time polymerase chain reaction in bone marrow neutrophils at 3 days post ischemia. A detailed description on subgroup allocation and exclusion criteria is given in the online-only Data Supplement.
Induction of Focal Cerebral Ischemia
Induction of stroke was performed using the intraluminal monofilament occlusion model as described previously. 4 A detailed description is given in the online-only Data Supplement.
Analysis of Poststroke Motor Coordination Deficits
Assessment of motor coordination deficits was performed on days 4, 7, and 14 using the rota rod and the tight rope test as previously described. 16 Details are given in the online-only Data Supplement.
Analysis of Postischemic Tissue Injury and Immunohistochemistry
For infarct volume measurement and immunohistochemical analysis, mice were transcardially perfused with ice-cold PBS at 72 hours post ischemia. Brains were removed and fresh-frozen on dry ice. To determine infarct volume, coronal cryostat brain sections (20 μm thick) taken at 400-μm intervals between +2 mm up to −4.4 mm from bregma were stained with cresyl violet. For assessment of cell death, endothelial activation, neutrophil infiltration, and oxidative DNA damage, cryostat sections taken at the level of bregma were used for immunohistochemistry according to published protocols. 4, 17 A detailed description of stainings and quantifications is given in the online-only Data Supplement.
Processing of Peripheral Blood, Bone Marrow, and Brain Tissues for Flow Cytometry Analysis
Isolation of single-cell suspension for flow cytometry analysis was performed as previously described. 4 Briefly, animals were euthanized by intraperitoneal injections of chloralhydrate (200 mg/kg body weight). Blood specimens were collected into EDTA-coated collection tubes by puncture of the inferior vena cava followed by transcardial perfusion with ice-cold PBS. Brains were dissected and hemispheres divided into ipsilesional and contralesional parts. Bone marrow from femurs and tibiae was flushed with PBS. A detailed description of further single-cell isolation, staining procedures, antibody cocktails, and gating strategies is given in the online-only Data Supplement (Methods and Table I in the online-only Data Supplement).
Gene Expression Analysis of Sorted Neutrophils by Real-Time Polymerase Chain Reaction
For gene expression studies, ex vivo isolated bone marrow cells were sorted for the neutrophil-specific antigen Ly6G using magnetic activated cell sorting (MACS). Total RNA was extracted from cell lysates (Promega, Madison) transcribed to complementary DNA followed by real-time polymerase chain reaction. Details on the experimental conditions and measurements, as well as primer sequences, are given in the online-only Data Supplement (Methods and Figure 1A and 1B) . Administration of the selective CXCR2 inhibitor SB225002 did not affect ischemic brain injury in normolipidemic wild-type mice, but reversed the increased brain injury in hyperlipidemic ApoE −/− mice ( Figure 1C and 1D ). This effect was mimicked by a neutralizing CXCR2 antiserum 15 ( Figure 2A ). To exclude the possibility that 72 hours was too late to detect differences in brain injury of normolipidemic mice, we also analyzed infarct volume at 24 hours post ischemia. Again, infarct volume was not altered by CXCR2 deactivation ( Figure I in the onlineonly Data Supplement). To test whether neuroprotective effects in hyperlipidemic mice were attributed to specific effects on neutrophils, we assessed infarct volume in ischemic mice, which had been neutrophil-depleted using a specific anti-Ly6G (1A8) antibody 11 and in which CXCR2 was inhibited with SB225002 ( Figure 2B ). Neutrophil depletion led to a significant reduction of infarct volume in hyperlipidemic ApoE −/− mice but not in normolipidemic wild-type mice ( Figure 2C ). Of note, administration of the CXCR2 antagonist did not further reduce infarct volume in neutrophil-depleted mice ( Figure 2C ), indicating that neuroprotection by SB225002 can be assigned to a direct effect on CXCR2-expressing neutrophils.
Inhibition of CXCR2 Reduces Neutrophil Infiltration Without Affecting Endothelial Activation
To analyze whether brain neutrophil invasion was blocked by pharmacological CXCR2 antagonization, we quantified cerebral neutrophils infiltrated in ipsilateral and contralateral hemispheres by flow cytometry. The CXCR2 antagonist SB225002 decreased neutrophil counts in ischemic hemispheres of ApoE −/− mice on Western diet and wild-type mice on normal diet ( Figure 3A) . Recruitment of other immune cell subsets was not significantly modulated by CXCR2 inhibition ( Figure  II in the online-only Data Supplement), suggesting a selective interaction with neutrophils. To exclude potential confounders related to differences in lesion size, we quantified the regional densities of neutrophils within the lesion rim by Ly6G immunohistochemistry and furthermore evaluated their localization with respect to brain capillaries in costainings with the panendothelial marker CD31. Although previous studies had shown a predominant association of neutrophils with ischemic brain vessels, 18 we observed a significant proportion of neutrophils in the brain parenchyma for all investigated groups ( Figure 3B ), closely in line with recent reports of others and us. 11, 19 The local distribution of neutrophils was not significantly modulated by hyperlipidemia or by administration of the CXCR2 antagonist SB225002 ( Figure 3B , top middle). Distances of intraparenchymal neutrophils to the most adjacent vessel were also not changed ( Figure 3B , top right). Therefore, we quantified the total number of neutrophils (vessel-associated and intraparenchymal) revealing significantly reduced numbers of neutrophils in the injured brain of ischemic hyperlipidemic ApoE −/− mice treated with SB225002 compared with vehicle-treated mice and ischemic normolipidemic wild-type mice ( Figure 3B , bottom). To avoid false interpretation because of unspecific effects of SB225002 on blood-brain barrier characteristics, which might have contributed to inhibition of neutrophil infiltration and tissue injury, we also performed a detailed analysis of blood-brain barrier integrity and endothelial activation. Except an increased blood-brain barrier permeability ( Figure IIIA in the online-only Data Supplement) and increased intracellular adhesion molecule-1 and vascular adhesion molecule-1 expression ( Figure 3C and 3D) in ischemic hyperlipidemic ApoE −/− mice compared with normolipidemic wild-type mice, no significant changes were induced by systemic SB225002 administration. The overall number of vessels was affected neither by hyperlipidemia nor by CXCR2 antagonization (Figure IIIB in the online-only Data Supplement). Therefore, reduced neutrophil infiltration might be directly attributed to the CXCR2-inhibitory effect of SB225002.
Peripheral Neutrophilia in Ischemic Hyperlipidemic ApoE −/− Mice Is Reduced by CXCR2 Antagonization
In addition to chemotactic activity, we examined whether modulation of CXCR2 changes the number of peripheral neutrophils. Analysis of the absolute viable neutrophil counts demonstrated that focal cerebral ischemia induced an increase in circulating and bone marrow neutrophils in hyperlipidemic ApoE −/− mice, which was inhibited by SB225002 (Figure 4 ). These data suggest that neutrophil homeostasis is altered in the bone marrow, Figure 2 . Anti-CXCR2 treatment results in similar neuroprotection as SB225002 whose neuroprotective capacity is abrogated in neutrophil-depleted hyperlipidemic ApoE −/− mice. Infarct volumes were determined in ischemic wild-type mice fed with normal chow (normolipidemic) or ApoE −/− mice fed with high cholesterol diet (hyperlipidemic) which received either anti-CXCR2 serum or normal rabbit serum (NRS) at 0, 24, and 48 hours post ischemia (A; n=8-9). For neutrophil depletion, normolipidemic wild-type and hyperlipidemic ApoE −/− mice were treated with anti-Ly6G or isotype control antibody 24 hours before and 24 hours post ischemia (B). The CXCR-2 inhibitor SB225002 (2 mg/kg, CXCR2 antagonist) or vehicle (1% dimethyl sulfoxide in PBS) was intraperitoneally injected at 0, 24, and 48 hours post ischemia (B and C; n=7-8). Infarct volumes were determined at 72 hours post ischemia using cresyl violet staining (A-C). MCAO indicates middle cerebral artery occlusion. *P<0.05, ***P<0.001. 
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October 2015 in addition to peripheral blood. Of note, neither focal cerebral ischemia nor CXCR2 antagonization by SB225002 influenced the number of blood and bone marrow neutrophils in normolipidemic wild-type mice (Figure 4) . In addition to an ischemiaindependent overall increase in myeloid cells in the blood and reduced lymphocyte numbers in the bone marrow of hyperlipidemic ApoE −/− mice, we observed an ischemia-induced reduction in lymphocyte subsets in all experimental groups ( Figure IV in the online-only Data Supplement). However, none of these immune cell subsets were regulated by the CXCR2 inhibitor, suggesting a selective interaction with neutrophils ( Figure IV in the online-only Data Supplement).
Stroke-Induced Reduction of Neutrophil Apoptosis and Increase in CXCR2 Expression on Bone Marrow Neutrophils of Hyperlipidemic ApoE −/− Mice Is Reversed by Antagonization of CXCR2
To explain the SB225002-mediated reduction in viable neutrophil counts in the periphery, we next evaluated neutrophil survival by quantifying the proportion of dead neutrophils by flow cytometry using propidium iodide. On CXCR2 antagonization, ischemic hyperlipidemic ApoE −/− mice revealed an increased proportion of dead neutrophils in the bone marrow ( Figure 5A ), suggesting that SB225002 counteracts the ischemia-induced increase of neutrophil survival in hyperlipidemic ApoE −/− mice. In normolipidemic wild-type mice, on the other hand, neither ischemia nor CXCR2 deactivation modulated the proportion of dead neutrophils ( Figure 5A ). To exclude any confounding effects by false-positive detection rarely associated with propidium iodide staining, we quantified the proportion of Annexin V positive bone marrow neutrophils in ischemic hyperlipidemic ApoE −/− mice either treated with vehicle or with the CXCR2 antagonist SB225002. Confirming propidium iodide measurements, increased numbers of apoptotic cells were noted in SB225002-treated mice ( Figure 5B) .
Next, we wondered whether CXCR2 expression on neutrophils was affected by hyperlipidemia or ischemia. Flow cytometry and real-time polymerase chain reaction revealed that CXCR2 protein and mRNA expression on bone marrow neutrophils were increased on ischemia in hyperlipidemic ApoE −/− mice, which were reversed through CXCR2 deactivation by SB225002 ( Figure 5C and 5D) . In normolipidemic wild-type mice, neither ischemia nor CXCR2 antagonization affected CXCR2 expression on bone marrow neutrophils ( Figure 5C and 5D ).
CXCR2 Antagonist SB225002 Modulates Oxidative Stress-Related Enzyme Expression in Bone Marrow Neutrophils and Reduces Oxidative Damage in Ischemic Brains of Hyperlipidemic ApoE −/− Mice
To further elucidate mechanisms for the differential effects of CXCR2 inhibition in normolipidemic and hyperlipidemic mice, we finally investigated whether oxidative stress-related enzyme expression was modulated by hyperlipidemia, ischemia, and CXCR2 antagonization. mRNA expression analysis of the inflammation-associated inducible nitric oxide synthase in sorted bone marrow neutrophils demonstrated that focal cerebral ischemia induces a strong increase in hyperlipidemic ApoE −/− but not in normolipidemic wild-type mice, which was reversed by CXCR2 blockade ( Figure 6A ). Moreover, a significant ischemia-induced decrease of NADPH oxidase 2 expression detected in normolipidemic wild-type mice was absent in hyperlipidemic ApoE −/− mice. However, CXCR2 deactivation by SB225002 reduced NADPH oxidase 2 expression in ischemic hyperlipidemic ApoE −/− mice to levels of ischemic normolipidemic wild-type mice ( Figure 6B ). We further observed an overall reduced expression of the antioxidative enzymes, catalase and superoxide dismutase 2, in ischemic and nonischemic hyperlipidemic ApoE −/− mice, which was not influenced by CXCR2 inhibition ( Figure V in the onlineonly Data Supplement). Taken together, these data suggest that hyperlipidemia combined with focal cerebral ischemia promotes an inflammatory and reactive oxygen species producing phenotype in ischemic hyperlipidemic ApoE −/− mice, which is partially counterbalanced by CXCR2 deactivation. In light of the presented results, we further analyzed oxidative DNA damage through immunohistochemical detection of 8-hydroxy-2′-deoxyguanosine (8-oxo-dG) as an indicator of oxidative stress. Quantification of 8-oxo-dG positive cells in ischemic brain tissue revealed that the CXCR2 antagonist SB225002 reduced increased levels of oxidative DNA damage in hyperlipidemic ApoE −/− mice, whereas normolipidemic wild-type mice exhibited an overall low density of 8-oxo-dG positive cells, which was not modulated by the CXCR2 antagonist ( Figure 6C ).
Discussion
Systemic inflammation is linked to stroke occurrence and severity. However, translation from bench-to-bedside targeting the immune system to prevent stroke or diminish damage has failed to date. One critical issue regarding the lack of successful translation is that underlying inflammation associated with comorbidity factors, such as hyperlipidemia, has been broadly neglected in most preclinical trials. We have previously shown that increased ischemic brain damage in hyperlipidemic mice coincides with increased cerebral and peripheral granulocyte numbers. 4 In this study, we provide the causal link between these observations by showing that pharmacological or antiserum-mediated antagonization of the neutrophil-specific chemokine receptor CXCR2 or anti-Ly6G antibody-induced neutrophil depletion restores functional outcome and reverses brain injury induced by hyperlipidemia, thereby unraveling the functional significance of neutrophils in the pathogenesis of ischemic brain injury. Interestingly, only hyperlipidemic mice were responsive to CXCR2 antagonization, cerebral neutrophil infiltration being strongly attenuated by CXCR2 inhibition in hyperlipidemic mice. This increased chemotactic activity of neutrophils in ischemic hyperlipidemic mice was most likely evoked by the increased CXCR2 expression on peripheral neutrophils, perhaps combined with the previously reported increase of its ligands CXCL1 and CXCL2 in ischemic brains of hyperlipidemic mice. 4 Chemotactic receptors, such as CXCR2, are involved in interactions with endothelial cells and platelets, which play an important role in atherosclerosis development 20 and which regulate neutrophil crawling in inflamed vessels. 21 Thus, brain platelet-neutrophil interactions 
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October 2015 might be associated with the initiation of neutrophil infiltration into the ischemic brain in hyperlipidemia. In addition to enhanced chemoattraction to the brain, elevated cerebral neutrophil counts in hyperlipidemic stroke mice might partially result from the overall increased number of circulating neutrophils induced by ischemia. Importantly, CXCR2 antagonization by SB225002 reversed this peripheral neutrophilia. Because increased circulating neutrophils were paralleled by increased bone marrow neutrophils, elevation of blood neutrophils caused by a CXCR2-dependent release from the bone marrow to the circulation 14 seems unlikely. Instead, stroke-induced survival of bone marrow neutrophils in hyperlipidemia was blocked by CXCR2 antagonization. Indeed, neutrophil viability has been shown to be regulated by chemokines in interaction with CXCR2. 22 Furthermore, CXCR2 antagonization increases neutrophil apoptosis in a concentration-dependent manner, 23 supporting our concept of induction of neutrophil apoptosis by the CXCR2 antagonist SB225002. The lack of apoptosis induction in sham-operated and ischemic normolipidemic mice might be explained by the lower CXCR2 expression. Thus, a certain chemokine receptor expression and activation level seems to be required for neutrophil survival.
Although CXCR2 blockade resulted in reduced cerebral neutrophil entry both in normolipidemic and hyperlipidemic mice, only hyperlipidemic mice benefited from CXCR2 inhibition, suggesting that in addition to the total number, the phenotype of neutrophils determines the impact on stroke outcome. We show that focal cerebral ischemia induces a strong increase of inducible nitric oxide synthase and NADPH oxidase 2 in neutrophils of hyperlipidemic mice, which is downregulated by CXCR2 inhibition. Both enzymes are involved in the generation of reactive oxygen/nitrogen species, one of the main effector functions of neutrophils in stroke pathology. 24, 25 Alterations of the neutrophil phenotype in ischemic hyperlipidemic mice were associated with an increased level of cerebral oxidative DNA damage, which was similarly reversed by CXCR2 deactivation as inducible nitric oxide synthase. These associated findings may indicate that decreased neutrophil activation and reactive oxygen species production through CXCR2 antagonization might present a potential mechanism underlying the observed neuroprotective effects in hyperlipidemic ischemic mice. This is further supported by a previous study reporting reduced myeloperoxidase activity of neutrophils after CXCR2 antagonization. 23 In light of previous Figure 6 . Expression of oxidative stress-related enzymes in bone marrow neutrophils and cerebral oxidative DNA damage of ischemic hyperlipidemic mice are modulated by CXCR2 antagonization. mRNA expression analysis of inducible nitric oxide synthase (iNOS; A) and NADPH oxidase 2 (NOX2; B) was analyzed in magnetic activated cell sorting-sorted Ly6G + bone marrow neutrophils at 72 hours post ischemia of wild-type mice fed a normal chow or ApoE −/− mice fed a Western diet for 6 weeks that were either sham operated or exposed to middle cerebral artery occlusion (MCAO) followed by intraperitoneal administration of the CXCR2 antagonist SB225002 (2 mg/kg) or vehicle (1% dimethyl sulfoxide in PBS) at 0, 24, and 48 hours post stroke. Mean values of ∆∆ct values are presented (relative expression, n=4-6). C, Oxidative DNA damage was analyzed by immunohistochemical detection and quantification of 8-hydroxy-2′-deoxyguanosine (8-oxo-dG) positive cells in ischemic brain tissue (n=4-6). Scale bar: 50 µm. **P<0.01, ***P<0.001. by guest on May 2, 2017 http://stroke.ahajournals.org/ Downloaded from studies suggesting a certain neutrophil plasticity similar to macrophage plasticity distinguishing proinflammatory M1 and anti-inflammatory M2 macrophages, 19, 26 increased levels of inducible nitric oxide synthase, a classical M1 marker, imply that the combination of brain ischemia and hyperlipidemia might induce a general switch of neutrophils to a proinflammatory N1 phenotype, which is reversed by CXCR2 antagonization. Additional studies will be required to characterize the whole repertoire of classical M1/N1 and M2/N2 markers in this specific experimental setting.
Despite reduced cerebral neutrophil infiltration, normolipidemic mice were not protected by CXCR2 inhibition. This observation appears to differ from recent studies, including our own, demonstrating neuroprotection by neutrophil depletion and blocking neutrophil invasion. [9] [10] [11] [12] The most likely explanation is the different severity of brain injury. Although the latter studies induced 45-and 60-minute MCAO, we used a mild ischemia model leading to much smaller infarcts and a lesser degree of neutrophil accumulation, suggesting that a certain threshold of cerebral neutrophil counts needs to be exceeded to uncover the cells' pathogenic role. However, even if more severe injury models are used, several studies interfering with CXCR2 signaling and thereby reducing neutrophil infiltration failed to influence stroke outcome in normolipidemic wildtype mice. [27] [28] [29] But most of these studies assessed stroke outcome at 24 hours post injury that might be too early to detect secondary neurodegeneration after the complex inflammatory cascade have been fully established. Although neutrophils are considered to be the first invaders of the ischemic brain, secondary recruitment of neutrophils through interleukin-17 producing γδ T cells peaking at 3 days post injury has been suggested. 30 Therefore, it cannot be excluded to detect protection in a more severe stroke model at 3 to 7 days post ischemia. In fact, administration of neutralizing CXCR2 serum in a severe transient MCAO model in normolipidemic wild-type mice results in significantly smaller infarct sizes 3 days after stroke. 30 However, Cuartero et al 19 demonstrated that neutrophil infiltration is maximal after 24 hours and that modification of neutrophil phenotype by rosiglitazone is associated with significantly reduced infarct volumes in normolipidemic mice at 24 hours post ischemia, indicating that 72 hours might have been too late to detect the impact of CXCR2 inhibition in normolipidemia. In our study, infarct volume in normolipidemic mice was unaffected by CXCR2 antagonization at 24 and 72 hours post stroke, demonstrating that the observations made did not depend on the selection of the time window. Nevertheless, specific characteristics of ischemia models (eg, distal versus intraluminal) should carefully be considered, when evaluating observations in earlier studies. 31 In conclusion, our study suggests that the contribution of neutrophils to the development of ischemic brain injury depends on the pathophysiological state. Thus, neutrophils have a unique role in stroke pathogenesis in hyperlipidemia. Similarly, differential roles of immune cell subsets have previously been shown for CCR2 + monocytes which are important for vascular stabilization in normolipidemic ischemic mice 32 but harmful in acute hyperlipidemia. 5 By showing that hyperlipidemic mice-unlike normolipidemic mice-respond to the inhibition of the neutrophil-specific chemokine receptor CXCR2, we provide a potential therapeutic strategy for attenuating the exacerbation of ischemic injury induced by hyperlipidemia. In the evaluation of new therapies, preclinical and clinical studies should carefully consider inflammationassociated comorbidities, namely hyperlipidemia, which, as we show, may alter the responsiveness of the ischemic brain tissue.
